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Perlecan, a large heparan sulfate proteoglycan, is a component of the basement membrane and other extracellular
matrices and has been implicated in multiple biological functions. Mutations in the perlecan gene (HSPG2) cause
two classes of skeletal disorders: the relatively mild Schwartz-Jampel syndrome (SJS) and severe neonatal lethal
dyssegmental dysplasia, Silverman-Handmaker type (DDSH). SJS is an autosomal recessive skeletal dysplasia char-
acterized by varying degrees of myotonia and chondrodysplasia, and patients with SJS survive. The molecular
mechanism underlying the chondrodystrophic myotonia phenotype of SJS is unknown. In the present report, we
identify five different mutations that resulted in various forms of perlecan in three unrelated patients with SJS.
Heterozygous mutations in two patients with SJS either produced truncated perlecan that lacked domain V or
significantly reduced levels of wild-type perlecan. The third patient had a homozygous 7-kb deletion that resulted
in reduced amounts of nearly full-length perlecan. Unlike DDSH, the SJS mutations result in different forms of
perlecan in reduced levels that are secreted to the extracellular matrix and are likely partially functional. These
findings suggest that perlecan has an important role in neuromuscular function and cartilage formation, and they
define the molecular basis involved in the difference in the phenotypic severity between DDSH and SJS.
Schwartz-Jampel syndrome (SJS [MIM 255800]) is a
rare autosomal recessive skeletal dysplasia associated
with myotonia (Aberfeld et al. 1965; Aberfeld et al.
1970). This disorder is characterized by short stature,
osteochondrodysplasia, myotonia, and a characteristic
face with a “fixed” facial expression, blepharophimosis,
pursed lips, and, sometimes, low-set ears and myopia.
Skeletal abnormalities include kyphoscoliosis, platy-
spondyly with coronal clefts in the vertebrae, metaphy-
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seal and epiphyseal dysplasias, and joint contractures.
Electromyography (EMG) shows persistent spontaneous
activity, particularly in the face and thigh muscles, which
tends to diminish at rest (Taylor et al. 1972; Jablecki
and Schultz 1982). This spontaneous activity decreases
with applications of curare in some patients, suggesting
that the disorder is of neurogenic origin (Taylor et al.
1972; Fowler et al. 1974). Muscle biopsies show non-
specific myopathy (Fowler et al. 1974; Pascuzzi 1991).
The clinical phenotype of SJS varies (Giedion et al.
1997). Mildly affected patients develop a moderate bone
dysplasia in childhood. In more severely affected pa-
tients, a more obvious bone dysplasia, reminiscent of
Kniest dysplasia, is present from infancy. Through link-
age mapping and a positional candidate approach, Ni-
cole et al. (2000) recently identified homozygous mu-
tations in HSPG2 in two families with SJS. The
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mutations involved missense and splicing inHSPG2, but
predicted mutant perlecan molecules have not been
characterized.
Perlecan is a multifunctional proteoglycan present in
all basement membranes and in cartilage (Iozzo et al.
1994; SundarRaj et al. 1995; French et al. 1999). The
protein core is ∼400 kD, with three covalently attached
heparan sulfate chains at the N-terminus and another
chain at the C-terminus (fig. 1D). Perlecan is implicated
in cell growth and differentiation, through interactions
with growth factors, cell surface receptors, and extra-
cellular matrix molecules (Noonan et al. 1991; Aviezer
et al. 1994; Dolan et al. 1997; Olsen 1999). The N-
terminal domain, domain I, contains attachment sites
for heparan sulfate chains and binds to growth factors
(Iozzo 1994) and acetylcholinesterase (Peng et al. 1999).
Domain IV binds basement membrane molecules, such
as nidogen/entactin and type IV collagen (Hopf et al.
1999). Domain V binds cell surface receptors such as a-
dystroglycan and integrin b1 (Brown et al. 1997; Fried-
rich et al. 1999).
The majority of mice with a homozygous null mu-
tation in the perlecan gene (Hspg2) develop severe chon-
drodysplasia and die, just after birth, of respiratory fail-
ure (Arikawa-Hirasawa et al. 1999; Costell et al. 1999).
Through comparison of skeletal abnormalities of human
patients to the perlecan-null mice, we recently identified
mutations in HSPG2 in a lethal autosomal recessive dis-
order termed “dyssegmental dysplasia, Silverman-Hand-
maker type” (DDSH [MIM 224410] )(Arikawa-Hira-
sawa et al. 2001). In DDSH, we found that truncated
perlecan molecules were not secreted into the extracel-
lular matrix, indicating that functional null mutations
of the perlecan gene cause DDSH.
In the present report, we have identified, among three
patients with SJS, five different mutations in HSPG2
(GenBank accession number M852890), which result in
different levels and forms of perlecan molecules. SJS per-
lecan molecules are secreted and partially functional, al-
beit in markedly reduced concentrations. Phenotypic dif-
ferences in DDSH and SJS appear to reflect differences
in the amount of functional perlecan in the matrix.
HSPG2 mutations in three patients with SJS were an-
alyzed by RT-PCR and genomic sequencing (fig. 1). Pa-
tient 1 was an 8-year-old boy, born normally to healthy
parents. At the age of 3 years, dysmorphic features were
noted that became gradually prominent and consisted of
tonic contraction of the facial muscles, micrognathia, low-
set ears with folded helices, medial displacement of the
outer canthi, narrow palpebral fissure, blepharophimosis,
microstomia and pursing of the lips, high arched palate,
cervical kyphosis, pes planus and valgus ankle formation,
bowing of the leg bones, kyphoscoliosis, and lumbar lor-
dosis. He had hypertrophic muscles and mild weakness
of the quadriceps muscles. The creatinine kinase level was
elevated (896 IU/liter); the EMG showed occasional my-
otonic discharges. Patient 2 was noted as having short
stature and micromelia and was admitted to the hospital
at 4 mo of age. Radiographs revealed square, flared ilia
and short, bowed long bones. At 3 years of age, he showed
thigh muscle hypertrophy and gastrocnemius muscle at-
rophy. Micrognathia, pursed lips, saddle nose, orbital hy-
pertelorism, low-set ears, and high arched palate were
noted. He showed a waddling gait, mild weakness of the
quadriceps muscle, and percussion myotonia. EMG re-
vealed myotonic and myopathic discharge. Necrotic and
regenerating fibers were also found. Patient 3 was first
reported as having micromelic chondrodysplasia (Steven-
son 1982) but was reevaluated as having SJS in 2000
(Spranger et al. 2000). Micrognathia, a prominent phil-
trum, and bowed long bones were noted at age 3 mo.
Radiographs revealed coronal clefts in the lumbar ver-
tebrae, deficient ossification in the dorsal vertebrae, and
squared, flared ilia. All long bones showed expansion of
the metaphyses. At 4 years of age, facial movement be-
came difficult because of stiffness, and the mouth opening
was restricted. EMG showed pseudomyotonic discharge
and rapid firing of single units in the brachioradial, del-
toid, and medial gastrocnemius muscles.
Patient 1 had heterozygous mutations. Allele 1 had
an ArG transition at the 4 position (donor site) of
intron 56 (73744 ArG) that resulted in exon skipping
of 56, whereas allele 2 of HSPG2 contained a fusion of
exons 60 and 61 that resulted in retention of intron 59
or intron 61 or in retention of both in the mutant tran-
scripts. The exon fusion occurred at the precise acceptor
and donor sites, probably by retrotransposition. The
exon fusion mutation created aberrant transcripts. It
also predicts the production of the wild-type transcript.
A different primer set from exons 56 and 62, which was
used to exclude a wild-type transcript from allele 1, con-
firmed the presence of the wild-type transcript, together
with aberrant splicing transcripts produced by allele 2
(data not shown). The aberrant splicing from the two
alleles is predicted to create premature termination co-
dons. Patient 2 had a GrA transition at the last nucle-
otide of exon 64 (8544 GrA) in allele 1. This transi-
tion mutation did not change an amino acid but result-
ed in skipping of exon 64. Allele 2 has a 9-bp deletion
(cagCTCCAG) at the acceptor junction of intron 66 and
exon 67 in allele 2 (n3 del9) that created abnormal
splicing, including total or partial retention of intron 66
or skipping of exon 67. All aberrant splicing products
are predicted to create premature termination codons.
Patient 3 had a 7,108-bp homozygous deletion begin-
ning at the 5′ portion of exon 96 (n21 del7108) and
extending well beyond the 3′ flanking sequence of
HSPG2. This deletion created two aberrant transcripts;
product 2 (derived from intron 95 retention) and prod-
uct 1 (resulting from failure of splicing of both introns

Reports 1371
Figure 1 Mutation analysis and schematic diagram of perlecan. A, Results of RT-PCR RNA from patient 1 fibroblasts, using primer sets
V and W and analyzed on 1% agarose gels as described elsewhere (Arikawa-Hirasawa et al. 2001). Sequencing revealed that product 1 from
allele 1 was missing the entire exon 56 sequence and that products 1, 2, and 3 from allele 2 retained intron sequences. Product 3 of allele 2
contains the sequence of intron 61, whereas products 1 and 2 contain either both introns 59 and 61 or intron 59, respectively. Exon 56 skipping
in allele 1 causes frameshift and is predicted to produce a premature termination codon in exon 57. The intron 59 retention of products 1 and
2 from allele 2 is predicted to produce a premature termination codon within intron 59, and the intron 61 retention of product 3 is predicted
a termination codon within intron 61. Genomic sequencing identified heterozygous mutations in an ArG transition at the 4 position (donor
site) of intron 56 (73744 ArG) in allele 1. Allele 2 showed a complete loss of intron 60, resulting in fusion of exons 60 and 61 in the perlecan
gene. The exon fusion mutation created aberrant transcripts, products 1, 2, and 3, but is also predicted to produce the wild-type product. Since
primer set W does not distinguish the wild-type product derived from alleles 1 or 2, we used a primer set from exons 56 and 62 to exclude a
wild-type transcript from allele 1, in which exon 56 is missing and confirmed the presence of the wild-type transcript together with aberrant
splicing transcripts produced by allele 2 (data not shown). B, Patient 2. RT-PCR was performed with RNA from skeletal muscle tissues of
patient 2, using primer sets X and KK. Sequencing of product 1 with primers X revealed exon 64 skipping, and products 1, 2, and 3 with
primers KK contained total or partial retention of intron 66. Product 4 with primers KK showed exon 67 skipping. Genomic sequencing revealed
a heterozygous mutation in a G to A transition at the donor site of exon 64 (8564 GrA) in allele 1 and a 9-bp deletion (cagCTCCAG) at the
acceptor junction of intron 66 and exon 67 in allele 2 (n-3 del9). C, Patient 3. RT-PCR was performed with RNA from patient 3 fibroblasts
using primer set Z. Product 1 contained sequences including introns 94 and 95. Product 2, a major product, contained intron 95. Sequencing
of the genomic PCR product revealed a 7,108-bp deletion beginning at the 5′ portion of exon 96 and extending to the 3′ flanking sequence of
HSPG2. The deletion results in aberrant splicing, including exon skipping and intron retention. Asterisk (*) indicates a premature termination
codon. Arrows indicate abnormally sized RT-PCR products. D, Schematic diagram of perlecan and its exon and domain structure. Primer
sequences for RT-PCR are as follows: V (forward, ATCACGGTCACAGTAACTGGGACC; reverse, CCTGCACCGTTACTGACGTG); KK
(forward, ATGGCACAAGCGTGGAGGAAACC; reverse, AGGCTTCTTGCTCAGGGCCTGG); W (forward, ATCCAGCAGCGCCTTAG-
TGG; reverse, CATGCCCATCAGAATTGAGTCAT); X (forward, CTCAACAACATCG ATGCCCTGGAG; reverse, CTCCAGCCCAGGACCC-
ATTCCT); and Z (forward, AGGCAAGGACTTCATCAGCCTCGGG; reverse, TCGACTTGGATGGAACCTCTGCGG).
94 and 95) are predicted to produce truncated proteins
missing ∼35 and ∼64 amino acids from the C-terminal,
respectively.
We next examined the expression of perlecan in mus-
cles from patients 1 and 2 by immunostaining with do-
main-specific antiperlecan antibodies (fig. 2). Perlecan
was localized in the control tissue in the basal lamina
of the muscle fibers and in the capillaries. Similar but
weaker staining for domains III–V was observed in the
muscles of patient 1 (fig. 2A), consistent with the pres-
ence of the wild-type transcript. We observed a similar
immunostaining of fibroblasts from patient 1 (data not
shown). In patient 2, domains III and IV were present
in the muscle at a reduced level compared with the con-
trol specimen, but domain V was missing, suggesting a
defect in domain V (fig. 1). The aberrant splicing tran-
scripts from both alleles of patient 2 are predicted to
produce truncated perlecan molecules that lack the C-
terminal part of domain IV and all of domain V. Thus,
the immunostaining results agree with the predicted
truncated proteins. We examined immunostaining of
cultured fibroblasts from patient 3, because no tissue
from a muscle biopsy of this patient was available. In
patient 3 fibroblasts, domains III–V were present in the
matrix but with significantly less staining than in the
control specimen (fig. 2B). Because a 7-kb homozygous
deletion in HSPG2 of patient 3 eliminates only 35–64
amino acids in the C-terminal domain V, these results
are consistent with the genetic analysis.
Perlecan secretion from fibroblasts of patients 1 and 3
was next examined using western blot analysis (fig. 3).
After removal of heparan sulfate chains by heparitinase
treatment, conditioned media from normal fibroblasts
showed a protein core of perlecan that was ∼400-kD.
Patient 1 fibroblasts secreted a 400-kD protein core in
significantly reduced amounts compared with the wild-
type protein core, supporting the presence of the wild-
type transcript. The fibroblasts also secreted a smaller
immunostainable band of ∼150 kD, which may be a de-
graded product as is seen in the control fibroblasts. Con-
ditioned media from patient 3 fibroblasts contained a 400-
kD protein, which is predicted to lack ∼35–64 C-terminal
amino acids. As with patient 1, the amount of perlecan
secreted was significantly reduced compared with that of
the control.
In the patients we studied for the present report, par-
tial functional mutations in HSPG2 caused SJS, which
is characterized by myotonia associated with a chon-
drodysplasia phenotype. Five mutations were identified
in three patients with SJS, with one homozygous and
four heterozygous mutations. These mutations produce
different forms of the perlecan molecule. In patient 1,
the staining of domain V in muscles was present at levels
similar to those of other domains, and western blot anal-
ysis showed no obviously truncated molecules. These
results suggest that, in patient 1, only the normal protein
is secreted in the matrix, although in a reduced amount.
The predicted truncated molecules were likely unstable
because of proteolytic degradation or instability of the
mutant transcripts. In patient 2, mutant perlecan lacking
domain V was produced with reduced levels, compared
with the control. In patient 3, a 7-kb homozygous de-
letion near the end of HSPG2 produces a nearly full-
length perlecan molecule at reduced levels.
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Figure 2 Immunostaining of perlecan in muscle tissues and cultured fibroblasts. A, Muscle tissue from patients 1 and 2 and from an
unaffected control subject, stained with domain-specific anti-perlecan antibodies as described elsewhere (Arikawa-Hirasawa et al. 2001, 2002).
In patient 1, antibodies to domains III–V stained the basal lamina of the muscle, whereas, in patient 2, domain V staining was absent. The
staining in muscle tissue of patient 1 is significantly reduced. B, Cultured fibroblasts from patient 3 stained with domain-specific anti-perlecan
antibodies and with anti-fibronectin polyclonal antibodies. Domains III–V stained the extracellular matrix at significantly reduced levels compared
to control fibroblasts, whereas fibronectin stained strongly in both.
In patients with DDSH, we did not detect perlecan in
the cartilage matrix or in the matrix from cultured fibro-
blasts (Arikawa-Hirasawa et al. 2001); however, in con-
trast to results in patients with DDSH, we found that
mutant perlecan molecules or reduced amounts of wild-
type perlecan are secreted and localized in the matrix of
tissues from patients with SJS. In DDSH, there is mucoid
degeneration of the resting cartilage, as well as abnormal
chondrocyte columnar structures and defective mineral-
ization of the growth plate. Although only limited infor-
mation is available about the histology of cartilage from
patients with SJS, there is a report that indicates poor
chondrocyte columnar organization in epiphyseal carti-
lage of one patient with SJS (Aberfeld et al. 1965). The
SJS perlecan molecules in the matrix are partially func-
tional, which results in a milder chondrodysplasia phe-
notype than that of DDSH. In normal growth-plate car-
tilage, perlecan likely strengthens the extracellular matrix
structure by interacting with other molecules. Impaired
cartilage matrix resulting from partially functional per-
lecan may contribute to the skeletal abnormalities in pa-
tients with SJS. Patients 2 and 3 showed obvious micro-
melia in their early infancy, but patient 1 showed a
chondrodysplasia phenotype that was not obvious until
the patient was 3–4 years of age. This difference may
result from the fact that only patient 1 produces the nor-
mal perlecan molecule. Because the truncated perlecan
molecules of patients 2 and 3 are defective in domain V,
the C-terminal domain V may be responsible for the early
onset of skeletal abnormalities. It is conceivable that do-
main V plays a role in matrix-cell interaction through its
binding to a chondrocyte receptor, such as integrin, pro-
viding stable formation of the cartilage matrix structure.
Some of the skeletal abnormalities, such as scoliosis and
hip degeneration, in patients with SJS could be caused,
in part, by the myotonia in SJS.
Another characteristic of the SJS phenotype involves
abnormal neuromuscular functions. A unique set of mol-
ecules—including acetylcholine esterase (AChE), acetyl-
choline receptor (AChR), and perlecan—cluster at sites
of nerve-muscle contact to form the neuromuscular junc-
tion (NMJ), where muscle contraction is initiated. The
collagen-tailed form of AChE is highly expressed in in-
nervated regions of skeletal muscle fibers and is attached
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Figure 3 Perlecan secreted by cultured fibroblasts in patients 1
and 3. Media from cultured normal or patient fibroblasts were con-
centrated, were then adjusted to contain 0.35g CsCl/g of 4M guani-
dine, and were centrifuged for 72 h at 40,000 RPM in a 50-Ti rotor
at 12C. A proteoglycan-containing fraction was pooled, concentrated,
and digested with 0.1 mU heparitinase and 0.25 mU chondroitinase
ABC (Seikagaku). Digested and undigested samples were electropho-
resed in 3%–8% polyacrylamide tris-acetate gels, were transferred to
nitrocellulose, and were blotted with polyclonal antibodies to the per-
lecan protein core. In patient 1, a perlecan protein core of ∼400 kD
was detected after heparitinase digestion, but the amount was reduced
significantly, correlating with the reduced amount of the wild-type
perlecan transcript. Heparitinase treatment is necessary for the blot-
ting, because perlecan-containing heparan sulfate chains do not trans-
fer well onto a membrane because of the negatively charged heparan
sulfate chains. As with patient 1, patient 3 fibroblasts secreted the 400-
kD perlecan core protein in much more reduced amounts than did the
control cells. The truncated perlecan in patient 3 is missing only
∼35–64 amino acids of the most C-terminal part of domain V, sug-
gesting the mutant perlecan to be almost the same size as the wild-
type perlecan. Asterisks (*) indicate positions of the ∼400-kD protein
core.
to the synaptic basal lamina (Massoulie et al. 1993). In
vertebrate skeletal muscle, ACh acts as a neurotransmitter,
and AChE is responsible for rapid termination of neu-
rotransmission, by hydrolyzing ACh at the synapse. In
vitro studies show that perlecan binds to AChE, suggest-
ing that perlecan is an acceptor site for AChE at the NMJ
(Peng et al. 1999). How do the perlecan defects cause the
myotonic phenotype of SJS? Unlike the mutations in per-
lecan-null mice and patients with DDSH, mutations in
the patients with SJS produce partially functional perlecan
molecules, which are present in the basal lamina of the
muscle. We recently demonstrated, using perlecan-null
mice, that clustering molecules, such as AChR and agrin,
were present at the NMJ but that AChE was completely
absent, indicating that perlecan is a key molecule for lo-
calizing AChE at the synapse (Arikawa-Hirasawa et al.
2002). The reduced amounts of either truncated or nor-
mal perlecan molecules may result in reduced clustering
of AChE at the SJS NMJ, which would likely cause a
greater concentration of ACh. This would stimulate
AChR activity and thus cause myotonia. This mechanism
is different from that of other hereditary myotonias,which
are caused by defects in muscle membrane proteins in-
volved in the sodium channel. Mutations in the gene
COLQ for a collagenlike subunit of AChE were reported
to cause end-plate AChE deficiency (EAD), which is char-
acterized by a congenital myasthenic syndrome associated
with weakness and fatigability on exertion (Donger et al.
1998; Ohno et al. 1998). In this disorder, AChE cannot
form a heteromeric asymmetric complex with COLQ, and
it is therefore inactive for enzymatic activity. The differ-
ence in the phenotype of SJS and EAD may result from
the difference of AChE activity. In SJS, normal AChE is
produced and clustered at the NMJ—although in reduced
amounts—whereas, in EAD, there is no active AChE.
Without any AChE activity, there is no recycling of ACh,
which may lead to excessive depletion of ACh that, in
turn, causes a myasthenic syndrome. Curare, which
blocks transmission, can abolish persistent spontaneous
activity of the electromyography in patients with SJS but
not in other myotonias that result from defects in muscle
membrane proteins (Taylor et al. 1972). This curare effect
is in concordance with our proposed mechanism by which
defects in perlecan cause SJS myotonia. However, in some
patients with SJS, curare does not arrest the spontaneous
activity (Spaans et al. 1990). This may result from a sec-
ondary defect in muscle membranes caused by mutations
in the perlecan gene. Chronic impairment of NMJ activity
due to increased levels of ACh is known to cause degen-
eration of the folds of the NMJ (Engel et al. 1977; Salpeter
et al. 1979). Less stable synaptic basal lamina structures
may be formed because of the significant reduction of
wild-type perlecan or because of mutant perlecan defec-
tive in domain V, which leads to reduced expression of
clustering molecules.
Recently, Spranger et al. reported that several other
skeletal disorders previously identified as chondrodys-
plasias, such as kyphomelic chondrodysplasia, micro-
melic chondrodysplasia, and Burton disease, can be re-
classified, on the basis of clinical examination, as SJS
(Spranger et al. 2000). One of the patients with SJS in
the present report was originally classified as having mi-
cromelic chondrodysplasia. Thus, the clinical phenotype
of SJS encompasses a broad spectrum. Molecular and
biochemical analysis of perlecan from these patients
should provide more insight into phenotype-genotype
correlations and functional domains of perlecan.
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